Equities research analysts expect that Nevro Corp (NYSE:NVRO) will announce sales of $107.38 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Nevro’s earnings, with estimates ranging from $106.10 million to $107.85 million. Nevro reported sales of $97.96 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 9.6%. The firm is expected to report its next quarterly earnings results after the market closes on Thursday, February 28th.

On average, analysts expect that Nevro will report full year sales of $386.26 million for the current fiscal year, with estimates ranging from $385.00 million to $387.13 million. For the next fiscal year, analysts anticipate that the business will post sales of $419.87 million, with estimates ranging from $414.92 million to $425.40 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Nevro.

A number of research firms recently weighed in on NVRO. UBS Group started coverage on shares of Nevro in a research report on Tuesday, November 27th. They set a “sell” rating and a $35.00 price target on the stock. Canaccord Genuity decreased their target price on shares of Nevro from $80.00 to $63.00 and set an “in-line” rating on the stock in a report on Tuesday, November 6th. They noted that the move was a valuation call. Northland Securities reiterated a “hold” rating and issued a $48.00 target price on shares of Nevro in a report on Friday, January 11th. Zacks Investment Research upgraded shares of Nevro from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a report on Wednesday, January 9th. Finally, Morgan Stanley lowered shares of Nevro from an “equal” rating to a “weight” rating and decreased their target price for the company from $65.00 to $43.00 in a report on Tuesday, November 6th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $58.00.

Several hedge funds have recently modified their holdings of the company. State Board of Administration of Florida Retirement System lifted its holdings in shares of Nevro by 3.5% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 15,679 shares of the medical equipment provider’s stock worth $610,000 after acquiring an additional 525 shares during the last quarter. Essex Investment Management Co. LLC lifted its holdings in shares of Nevro by 31.8% in the 3rd quarter. Essex Investment Management Co. LLC now owns 11,473 shares of the medical equipment provider’s stock worth $654,000 after acquiring an additional 2,770 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in shares of Nevro in the 4th quarter worth approximately $113,000. HRT Financial LLC acquired a new position in shares of Nevro in the 3rd quarter worth approximately $208,000. Finally, Gamco Investors INC. ET AL lifted its holdings in shares of Nevro by 24.7% in the 4th quarter. Gamco Investors INC. ET AL now owns 20,200 shares of the medical equipment provider’s stock worth $786,000 after acquiring an additional 4,000 shares during the last quarter.

NVRO opened at $47.51 on Friday. The stock has a market cap of $1.42 billion, a P/E ratio of -38.01 and a beta of 0.18. Nevro has a twelve month low of $34.75 and a twelve month high of $94.34. The company has a current ratio of 8.05, a quick ratio of 6.31 and a debt-to-equity ratio of 0.62.

Nevro Company Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Article: What is a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.